Anavex Life Sciences

Anavex Life Sciences is a publicly traded biopharmaceutical company focused on developing novel therapeutics for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. Its lead candidate, ANAVEX 2-73 (blarcamesine), targets the SIGMAR1 receptor and has advanced through multiple clinical trials. The company leverages a precision medicine platform to address central nervous system diseases and aims to establish itself as a leader in targeted CNS therapeutics.

Company Facts

• Headquarters: New York, United States
• Founded: 2004
• Employees: 42
• Type: Public Corporation
• Website: https://www.anavex.com
• Industries: Biotechnology, Pharmaceuticals, Healthcare, Precision Medicine